Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 5/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107899 | 0.90 | PPARA (0.42) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4109851 | 0.86 | HSP90AA1 (0.43) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4110165 | 0.85 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4115064 | 0.84 | RARA (0.47) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4108263 | 0.82 | DHFR (0.40) | ALDH1A1MAPTLTA4HGAA | |
| SCHEMBL4107119 | 0.81 | NOS1 (0.48) | KDM4EALDH1A1LTA4H | |
| SCHEMBL4102085 | 0.79 | NPC1 (0.44) | LTA4H | |
| SCHEMBL4107011 | 0.79 | NPC1 (0.47) | ALDH1A1MAPTTP53 | |
| SCHEMBL4108177 | 0.78 | DHFR (0.50) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4103587 | 0.78 | GHSR (0.41) | KDM4EALDH1A1HPGDLTA4HGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | KDM4E 2414/4885ALDH1A1 1721/4885HSD17B10 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.